FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer Seite 1

19.04.2024 - Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an ... Seite 1

Related Keywords

Levi Garraway ,Ken Culver ,Drug Administration ,Head Of Global Product Development ,Clinical Affairs ,Thenational Comprehensive Cancer Network ,National Comprehensive Cancer Network ,Chief Medical Officer ,Global Product ,Roche Holding Aktie ,